In recent years, a member of the tumor necrosis factor (TNF) family, soluble human B Lym-phocyte Stimulator protein (BLyS), also referred to as B-cell activating factor (BAFF) and TNFSF13B has been studied extensively. Therefore, it is a priority to develop better treatments with fewer adverse events that can be used at different stages of disease activity. Drug metabolism and clearance may be severely compromised. In some patients, the response is inadequate and side effects appear from mild unpleasant up to severe toxicity. There have been few changes over the last 50 years in the treatment of Systemic lupus erythematosus (SLE), using non-specific anti-inflammatory agents such as: non-steroidal anti-inflammatory drugs along with the immune cell modulating agent hydroxy-chloroquine for mild disease, and broad spectrum immunosuppressants plus anti-inflammatories such as corticosteroids, azathioprine, cyclophosphamide, or mycophenolate during flares or severe disease with organ involvement.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |